Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.

摘要: Quantitative PCR (qPCR) for detection of fusion transcripts and overexpressed genes is a promising tool following minimal residual disease (MRD) in patients with hematological malignancies. Its widespread clinical use has to some extent been hampered by differences data analysis presentation that complicate multicenter trials. To address these issues, we designed highly flexible MRD-reporting software program, which from various qPCR platforms can be imported, processed, presented uniform manner generate intuitively understandable reports. The was tested two-step quality control (QC) study; the first step involved eight centers, whose previous experience ranged none extensive. participants received cDNA consecutive samples BCR-ABL+ chronic myeloid leukemia (CML) patient an acute (AML) both CBFβ-MYH11 WT1 target genes, they conducted on their respective hardware generated series reports pre-defined features. In two, five centers used report MRD harmonized manner, applying recently obtained CML international scale conversion factors. QC study demonstrated this suitable efficient handling data, generation harmonization data.